Pfizer Inc.: Pfizer and BioNTech Announce Updated Clinical D

Bivalent booster elicited approximately 4-fold higher neutralizing antibody titers against Omicron BA.4/BA.5 sublineages compared to the original COVID-19 vaccine in individuals older than 55 years

Related Keywords

United States , Canada , United Kingdom , Sylke Maas , Biontech Covid , Albert Bourla , Ugur Sahin , Fosun Pharma , Centers For Disease , Linkedin , Genentech , European Commission , Drug Administration , Exchange Commission , Pfizer , Youtube , Pfizer Inc , European Union , European Medicines Agency , Roche Group , Chief Executive Officer , Marketing Authorization Holder , Emergency Use Authorization , Coronavirus Disease , Disease Control , Vaccine Adverse Event Reporting System , Prescribing Information , Vaccination Providers , Caregivers Fact Sheets , Breakthroughs That Change Patient , Pfizer News , Annual Report , Looking Information , Factors That May Affect Future , New Technologies , Private Securities Litigation Reform Act , Quarterly Report , Iontech , Nnounce , Pdated , Linical , Data , Micron , Adapted , Bivalent , Rooster , Emonstrating , Substantially , Higher , Immune , Response , Adults , Ompared , Original , Covid , Vaccine ,